Advanced therapies
A collaborative partnership, distributed ecosystem, for accelerating innovation in advanced therapies.
What is BioPharmaX ?
It is a collaborative partnership that brings together different disciplines, stakeholders, initiatives and disease domains.
Unlike consortia, networks, or alliances the goal is to bring collaborators and competitors together in what can be best described as a virtual, or distributed, ecosystem.
Within the framework of the distributed translational ecosystem partners:
Share knowledge (technology/method scan seminars, biotech advisory sessions)
Collaborate on data exploration and analysis
Engage in pilot studies that help shape the future directions and lead to new projects
Work together to make the most out of public and private funding
Participate in a stakeholder-centered strategic planning process on how to move precision medicine forward
Most importantly the ecosystem is a way to work on innovation bottlenecks as a way to create awareness and build trust resulting in new multi-partner and smaller-scale collaborative projects.
Initiatives we are bringing together
T2EVOLVE: An Innovative Medicines Initiative funded public/private partnership focused on innovation bottlenecks in engineered cell therapy development. Consists of six major pharma, 15 academic institutions, four SMEs, a patient organization, and a professional society. Learn more.
imSAVAR: A public/private partnership funded by the Innovative Medicines Initiative focused on building better preclinical models for safety testing of immune system modulating therapeutics.
A consortium of nine major pharma, 13 academic institutions, one patient organization, and four SMEs. Learn more.
Aerosolized medicines alliance: An alliance of industry and institutes dedicated to delivering a platform that aims to bring the benefits of aerosolized medicines to the field of advanced therapies.
Consists of five institutes, and four Biotech SMES.
Our vision of the future
The vision of the T2EVOLVE consortium is is to build alignment within the engineered cell therapy community to accelerate the pace of innovation.
Accelerating engineered cell therapy development
Enabling aerosolized advanced therapies
The Aerosolized Medicines Alliance envisions the development of a platform of models, and assessments that will resolve innovation bottlenecks in aerosolized medicine.
Predicting toxicity
imSAVAR aims to use immune related adverse outcome pathways (irAOPs) to get alignment and improve the efficiency of toxicity testing for immunomodulatory therapies.
Updates
Why become a partner?
-
Unlike networks or alliances, BioPharmaX ecosystems are about working together to reduce innovation bottlenecks. There is no better way to build trust and to get to know future partners than working together on pilot projects that don’t risk exposing your intellectual property. Full members also get the opportunity to present in technology scans, exploratory data workshops and spotlight sessions.
-
One thing that we have learned over the years is that when industry partners are working in a close partnership with academia the volume of publications increases, and industry partners become co-authors.
-
Over the years we have seen various early career researchers move out of academia and into industry through collaborative projects. In BioPharmaX ecosystems fosters opportunities for talent acquisition by showcasing early career researchers and highlighting their successes.
-
BioPharmaX is about projects that are of interest to both funding agencies and private companies. It is also about bringing the value of collaborative ventures to investors.
-
Data is an increasingly important ingredient for life sciences and healthcare innovation. Nonetheless it often remains in silos. BioPharmaX ecosystems place data at the core by increasing awareness about datasets and samples and making them available for projects and internal use. New initiatives that join bring access to additional datasets and samples.
-
There is no better way to understand new technology and emerging assets than working together with those who know it well. In technology scans, members present their latest technology and methods helping BioPharmaX members stay abreast with what is state-of-the art as well as cutting edge in the field.
-
When multiple disciplines and stakeholders work together to solve problems, knowledge is generated. It is a type of knowledge that is not easy to find elsewhere. In a BioPharmaX Ecosystem we structure that knowledge so partners can more easily absorb and make use of it.
-
Viewing profiles and presentations is a good way to evaluate potential partners. An even better way is to see how they work in a collaborative effort to solve innovation bottlenecks or as part of a pilot study. All of these types of activities will take place in BioPharmaX.
-
It is becoming more and more apparent that new therapeutics have the potential to treat more than one disease. A BioPharmaX ecosystem is where different disciplines interact across disease domains to find ways to repurpose therapies and extend the range of diagnostic and stratification approaches.
-
True exponential potential of any collaborative endeavour is realized when a critical mass of different stakeholders work together to solve innovation bottlenecks such as producing new regulatory frameworks, new standards, common protocols, or aligning on preclinical models. ABiopharmaX ecosystem is a source for new projects addressing innovation bottlenecks through low resource collaborative efforts or public funding such as the Innovative Health Initiatives.
-
The essence of a fruitful collaboration is generating more value together. BioSci Consulting’s substantial experience in designing and guiding public/private partnerships enables us to serve as a bridge between academia and industry to help ensure that what is created is of value to all.
-
Each year the BioPharmaX ecosystem will come together to create a multi-stakeholder driven strategic plan. This helps establish the collaborative culture so that subsequent interactions help develop and realize true collaborative partnerships. A BioPharmaX ecosystem is where meaningful stakeholder engagement shapes future research to be most impactful.